1:1, 2:1 OR 3:1 COMPLEX CONSISTING OF A CYCLODEXTRIN OR CYCLODEXTRIN DERIVATIVE AND A HALOGENATED ETHER, PRODUCTION THEREOF AND USE THEREOF AS SOPORIFIC

PURPOSE: A complex containing cyclodextrin or cyclodextrin derivative and low molecular halogenated ether is provided to enable controlled release of narcotic and to be used as a somnifacient. CONSTITUTION: A complex contains cyclodextrin or cyclodextrin derivative and low molecular halogenated ether mixed in a ratio of 1:1, 2:1, or 3:1. The halogenated ether has 4 or less of carbon atoms and is sevoflurane, isoflurane, or desflurane. The cyclodextrin is alpha, beta, or gamma-cyclodextrin. The cyclodextrin is methyl, sulfobutyl ether, and hydroxypropyl derivative of the alpha, beta, or gamma cyclodextrin. A method for preparing the complex comprises: a step of mixing an aqueous formulation and halogenated ether in a ratio of 4:1-35:1; a step of charging the aqueous formulation; and a step of adding halogenated ether. A pharmaceutical composition contains the complex and is manufactured in the form of tablet, coated tablet, or aqueous formulation.